Introduction:

Serum carcinoembryonic antigen (CEA) is prognostic for recurrence and survival in treated NSCLC. This prospective observational study evaluated CEA as a prognostic or surveillance biomarker in resectable early NSCLC.

Materials and methods: 

18 patients with histologically confirmed early NSCLC (stage I-IIIA) were recruited from October 2019 to January 2021. The serum CEA was measured pre-operatively, and then at 6, 12, 18 and 24 months post-operatively, in conjunction with routine CT and/or CT-PET surveillance scans.

Results: 

All patients had a curative R0 anatomical resection (lobectomy) with concurrent systematic mediastinal nodal dissection via a uniportal minimally invasive approach under single lung ventilation general anaesthesia. There was no operative, in-hospital or 30-day mortality. 7 patients (39%) had an elevated pre-operative baseline CEA level > 5.0ng/ml. The mean number of nodes sampled intraoperatively was 15. At median follow-up of 42 months, 11/18 (61.1%) patients were recurrence-free. There were no deaths and two recurrences (18.2%) amongst patients with a CEA < 5 (n=11). In the CEA > 5 subgroup (n=7), there were two deaths (28.5%) and 5/7 (71.4%) patients had a radiological recurrence. There was no difference in overall survival however disease-free survival (DFS) was significantly inferior in patients with a baseline CEA > 5. Median DFS was not reached in patients with CEA < 5 and 18 months in those with an elevated CEA > 5 (p<0.001) Conclusion: Almost 40% of local NSCLC patients had an elevated baseline CEA suggesting this is a useful prognostic and surveillance biomarker to incorporate in the routine work-up for any newly diagnosed NSCLC. Despite curative R0 resection and extensive intra-operative mediastinal lymph node sampling, an elevated pre-operative CEA was associated with a significantly reduced DFS and may be a surrogate for more aggressive tumour biology. Such patients will benefit from meticulous post resection surveillance and adjuvant therapy beyond conventional TNM criteria.

1. American Cancer Society. (2024). Global cancer facts & figures (5th ed.). American Cancer Society, Inc.
2. Al-Kattan, K., Sepsas, E., Fountain, S. W., & Townsend, E. R. (1997). Disease recurrence after resection for stage I lung cancer. European Journal of Cardio-Thoracic Surgery, 12(3), 380–384. https://doi.org/10.1016/S1010-7940(97)00192-3
3. Hoffman, P. C., Mauer, A. M., & Vokes, E. E. (2000). Lung cancer. The Lancet, 355(9202), 479–485. https://doi.org/10.1016/S0140-6736(00)01025-2
4. Carnio, S., Novello, S., Papotti, M., Loiacono, M., & Scagliotti, G. V. (2013). Prognostic and predictive biomarkers in early stage non-small-cell lung cancer: Tumour-based approaches including gene signatures. Translational Lung Cancer Research, 2(5), 372–381. https://doi.org/10.3978/j.issn.2218-6751.2013.10.02
5. Stieber, P., Hatz, R., Holdenrieder, S., Molina, R., Nap, M., Von Pawel, J., Loucka, M., & National Academy of Clinical Biochemistry. (2006). National Academy of Clinical Biochemistry guidelines for the use of tumor markers in lung cancer. Tumor Biology, 27(2), 81–111. https://doi.org/10.1159/000092305
6. Grunnet, M., & Sorensen, J. B. (2012). Carcinoembryonic antigen (CEA) as tumour marker in lung cancer. Lung Cancer, 76(2), 138–143. https://doi.org/10.1016/j.lungcan.2011.11.012
7. Molina, R., Filella, X., Augé, J. M., Fuentes, R., Bover, I., Rifa, J., Moreno, V., Canals, E., Viñolas, N., Bedini, J. L., & Ballesta, A. M. (2003). Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors. Tumour Biology, 24(4), 209–218. https://doi.org/10.1159/000074431
8. Kao, C. H., Hsieh, J. F., Ho, Y. J., & Ding, H. J. (1999). Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma. Lung, 177(5), 333–337. https://doi.org/10.1007/m004089900037
9. Nasralla, A., Lee, J., Dang, J., & Turner, S. (2020). Elevated preoperative CEA is associated with subclinical nodal involvement and worse survival in stage I non-small cell lung cancer: A systematic review and meta-analysis. Journal of Cardiothoracic Surgery, 15, Article 318. https://doi.org/10.1186/s13019-020-01358-x
10. Hsu, W. H., Huang, C. S., Hsu, H. S., Huang, W. J., Lee, H. C., Huang, B. S., Shih, C. C., & Chou, T. Y. (2007). Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. The Annals of Thoracic Surgery, 83(2), 419–424. https://doi.org/10.1016/j.athoracsur.2006.09.006
11. Jiao, Z., Cao, S., Li, J., Hu, N., Gong, Y., Wang, L., & Han, Z. (2021). Clinical associations of pre-operative and postoperative serum CEA and lung cancer outcome. Frontiers in Molecular Biosciences, 8, Article 686313. https://doi.org/10.3389/fmolb.2021.686313
12. Tomita, M., Ayabe, T., Chosa, E., & Nakamura, K. (2015). Postoperative serum CEA level is a more significant prognostic factor than post/preoperative serum CEA ratio in non-small cell lung cancer patients. Asian Pacific Journal of Cancer Prevention, 16(17), 7809–7812. https://doi.org/10.7314/apjcp.2015.16.17.7809
13. Sachithanandan, A., Lockman, H., Azman, R. R., Tho, L. M., Ban, E. Z., & Ramon, V. (2024). The potential role of artificial intelligence-assisted chest X-ray imaging in detecting early-stage lung cancer in the community—A proposed algorithm for lung cancer screening in Malaysia. Medical Journal of Malaysia, 79(1), 9–14.